Hosted on MSN
Long Shortz with Neurizon: FDA greenlight clears path for NUZ-001 to join landmark ALS trial
Stockhead’s Fraser Palamara chats with Neurizon Therapeutics (ASX: NUZ) managing director and CEO Dr Michael Thurn after the US FDA lifted the clinical hold on NUZ-001, clearing the way for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback